JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 163 filers reported holding JUNO THERAPEUTICS INC in Q4 2015. The put-call ratio across all filers is 2.35 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $845,000 | +5.9% | 18,479 | +3.8% | 0.00% | 0.0% |
| Q3 2017 | $798,000 | +50.0% | 17,799 | 0.0% | 0.00% | +100.0% |
| Q2 2017 | $532,000 | -4.5% | 17,799 | -29.1% | 0.00% | 0.0% |
| Q1 2017 | $557,000 | +12.5% | 25,087 | -4.4% | 0.00% | 0.0% |
| Q4 2016 | $495,000 | -39.9% | 26,244 | -4.3% | 0.00% | -50.0% |
| Q3 2016 | $823,000 | -19.4% | 27,411 | +3.2% | 0.00% | -33.3% |
| Q2 2016 | $1,021,000 | +340.1% | 26,556 | +402.9% | 0.00% | +200.0% |
| Q4 2015 | $232,000 | +3.1% | 5,281 | -4.7% | 0.00% | 0.0% |
| Q3 2015 | $225,000 | -23.2% | 5,541 | +1.0% | 0.00% | 0.0% |
| Q2 2015 | $293,000 | +1.4% | 5,487 | +15.0% | 0.00% | 0.0% |
| Q1 2015 | $289,000 | – | 4,771 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |